Dupilumab Approved in China as First Long-Acting Nasal Polyp Therapy, Impacting Global Prescription Drug Procurement

Introduction

On April 9, 2026, China's National Medical Products Administration (NMPA) approved GSK's dupilumab (branded as Eysuvis) for treating chronic rhinosinusitis with nasal polyps (CRSwNP) in adults, marking it as the world's first ultra-long-acting (only 2 doses per year) type 2 inflammation-targeted therapy. The approval, following prior FDA and EMA clearances, strengthens its global clinical evidence chain and accelerates registrations in Asia-Pacific and Latin American emerging markets. This development is particularly relevant for pharmaceutical distributors, importers, and CDMO providers, offering new opportunities in high-compliance biologic therapies for chronic diseases.

Event Overview

The NMPA's approval of dupilumab on April 9, 2026, positions it as a breakthrough for CRSwNP treatment, requiring just two annual injections. Previously approved by the FDA and EMA, this decision reinforces its global credibility and is expected to expedite market entries in emerging regions. The therapy's high compliance rate and targeted mechanism make it a significant addition to chronic disease management.

Impact on Sub-Sectors

Pharmaceutical Distributors and Importers

The approval opens new procurement channels for overseas distributors, particularly in markets with high demand for biologics. Its long-acting nature reduces logistical burdens, making it attractive for cross-border trade.

CDMO and Supply Chain Providers

Chinese CDMOs stand to benefit from increased orders for fill-finish and cold-chain export services, given the drug's temperature-sensitive requirements. Local manufacturers should prepare for potential partnerships with GSK or its affiliates.

Emerging Market Regulators

Regulatory bodies in Asia-Pacific and Latin America may fast-track approvals based on China's decision, creating a ripple effect in regional drug accessibility.

Key Focus Areas and Recommendations

Monitor Regulatory Follow-Ups

Track NMPA's post-approval guidelines and any adaptations for local production or distribution.

Assess Supply Chain Readiness

Distributors should evaluate cold-chain capabilities to handle dupilumab's storage requirements.

Explore Partnership Opportunities

CDMOs and logistics firms should engage with GSK’s regional teams to secure contracts for fill-finish or export services.

Editor’s Observation

From an industry perspective, this approval signals China's alignment with global drug evaluation standards, potentially easing future biologics approvals. While immediate commercial impacts may be limited to CRSwNP treatment, the precedent could accelerate similar therapies for other chronic conditions. Stakeholders should view this as a strategic inflection point rather than an isolated event.

Conclusion

China’s approval of dupilumab underscores its role in shaping global pharmaceutical trends, particularly for biologics. For industry players, this represents a dual opportunity: accessing a novel therapy for underserved markets and leveraging China’s manufacturing ecosystem for global supply. The focus should now shift to operationalizing distribution and partnerships.

Sources: NMPA announcement (April 9, 2026), GSK press release. Ongoing monitoring required for regional rollout timelines.